| 5.305 -0.135 (-2.48%) | 08-28 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.52 | 1-year : | 7.62 |
| Resists | First : | 5.59 | Second : | 6.52 |
| Pivot price | 5.27  |
|||
| Supports | First : | 4.88 | Second : | 4.44 |
| MAs | MA(5) : | 5.36 |
MA(20) : | 5.24 |
| MA(100) : | 6.06 |
MA(250) : | 6.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 78.9 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 9.93 | Low : | 4.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VNDA ] has closed below upper band by 49.2%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.5 | 5.5 - 5.53 |
| Low: | 5.2 - 5.23 | 5.23 - 5.26 |
| Close: | 5.39 - 5.44 | 5.44 - 5.48 |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Wed, 26 Aug 2026
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Wed, 26 Aug 2026
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Tue, 25 Aug 2026
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Wed, 19 Aug 2026
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
Mon, 17 Aug 2026
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 7,420 (K) |
| Shares Short P.Month | 7,340 (K) |
| EPS | -4.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.67 |
| Profit Margin | -127.5 % |
| Operating Margin | -126.3 % |
| Return on Assets (ttm) | -22.4 % |
| Return on Equity (ttm) | -77.9 % |
| Qtrly Rev. Growth | -4 % |
| Gross Profit (p.s.) | 3.34 |
| Sales Per Share | 3.56 |
| EBITDA (p.s.) | -2.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -142 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -1.14 |
| PEG Ratio | 2.2 |
| Price to Book value | 1.13 |
| Price to Sales | 1.48 |
| Price to Cash Flow | -2.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|